LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023.

The Alzheimer’s disease blood test developer C2N Diagnostics has released a new version of its screener for beta amyloid proteins, and it’s gearing up for a nationwide rollout as public hopes rise for treatments that may make some headway against the condition.

Medtronic (MDT.N) on Tuesday raised its annual profit forecast as the return of non-urgent surgery volumes to pre-pandemic levels boosted demand for its medical devices, sending its shares up 3%.

Not long after acquiring Resolution Bioscience in a deal worth more than half a billion dollars, Agilent Technologies has resolved to shutter the business, which was developing liquid biopsy tests that were powered by next-generation sequencing technology and meant to be used as companion diagnostics for cancer patients.

Geneseeq Technology Inc. has announced that three of our next-generation sequencing (NGS)-based cancer genetic testing kits, GENESEEQPRIME NGS Tumor Gene Detection Kit (GeneseeqPrime ™), GENESEEQ Homologous Recombination Deficiency Detection Kit (GeneseeqPrime™ HRD), and GENESEEQ Blood Cancer Gene Detection Kit (Hemasalus™ DNA/Hemarna™ RNA), have obtained the European Union’s CE Mark approval.

China Association of In Vitro Diagnostics (CAIVD) and In Vitro Diagnostics Society of China Association for Medical Devices Industry jointly compiled this report.

A new blood test is being developed to improve ovarian cancer diagnosis, with the potential to reduce unnecessary surgery leading to better health outcomes, saving time, stress and money for patients as well as the healthcare system.

To accelerate access to diagnostics in the continent, Africa CDC in partnership with key partners have launched the Africa Collaborative Initiative to Advance Diagnostics (AFCAD).

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

South Korean next-generation sequencing-based diagnostic firm NGeneBio said on Friday that it has entered a collaboration agreement with Chinese sequencing platform company MGI Tech to expand the commercial access of NGeneBio's cancer testing products.

Digital pathology firm Paige said Thursday it has forged a partnership with Ohio State University's Wexner Medical Center for a study to evaluate the use of artificial intelligence-assisted tools to diagnose prostate cancer in a community hospital setting.

Laboratory services company Labcorp has accelerated a strategy to drive growth through a string of healthcare system acquisitions and partnerships as its COVID PCR testing volumes have tapered off.

Wren Laboratories announced Thursday that it finalized a distribution agreement with Kindstar Globalgene Technology to distribute Wren's blood-based neuroendocrine tumor NETest throughout China.

GenInCode announced Wednesday that it filed a 510(k) submission for its CARDIO inCode-Score (CIC-Score) in vitro polygenic risk score (PRS) test for cardiovascular disease with the US Food and Drug Administration.

Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global science and technology innovator, today published its 2023 Sustainability Report which conveys the depth and scope of Danaher's sustainability program and highlights important milestones the Company achieved during the past year.